Compare GEOS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GEOS | IOVA |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.6M | 968.6M |
| IPO Year | 1997 | N/A |
| Metric | GEOS | IOVA |
|---|---|---|
| Price | $17.35 | $2.78 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $10.45 |
| AVG Volume (30 Days) | 220.5K | ★ 11.3M |
| Earning Date | 02-04-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $110,803,000.00 | ★ $250,425,000.00 |
| Revenue This Year | N/A | $60.71 |
| Revenue Next Year | N/A | $59.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $5.51 | $1.64 |
| 52 Week High | $29.89 | $8.15 |
| Indicator | GEOS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 64.22 |
| Support Level | $15.84 | $2.08 |
| Resistance Level | $18.70 | $2.99 |
| Average True Range (ATR) | 1.29 | 0.17 |
| MACD | 0.62 | 0.06 |
| Stochastic Oscillator | 71.96 | 77.47 |
Geospace Technologies Corp is engaged in designing and manufacturing sophisticated technology solutions for applications in smart water management, energy exploration, as well as industrial and Internet of Things. Its seismic equipment is used to locate, characterize, and monitor hydrocarbon reservoirs and is also marketed for vibration monitoring, security, and geotechnical uses. The company also produces non-seismic products such as Hydroconn cables, imaging equipment, remote shutoff water valves, and IoT platforms, and provides contract manufacturing services. The company's business segments includes Smart Water, Energy Solutions and Intelligent Industrial. The majority of its revenue is generated from the Energy Solutions segment.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.